|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.6350 - 0.7000|
|52 Week Range||0.4728 - 1.2778|
|Beta (3Y Monthly)||6.03|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
TORONTO , April 3, 2019 /CNW/ - Liberty Health Sciences Inc. (LHS.CN) (OTCQX: LHSIF) www.libertyhealthsciences.com ("Liberty" or the "Company"), a provider of high quality cannabis, announced today that it will open its 13th Florida dispensary in Bonita Springs on April 5 th, as the company continues to expand rapidly throughout the state. On April 1 st the Company also received approval form the Florida Department of Health (DOH) for an additional use of 80,000 square feet of enclosed greenhouse space at the Liberty 360 Innovation campus in Gainesville .
Liberty will be one of the first companies to offer pre-rolls of cannabis in a variety of strains and potencies, which will be available for purchase in Liberty dispensaries across the state. Patients will now be able to smoke the substance legally under a bill (SB 182) signed into law last week by Governor Ron DeSantis , which revoked the existing ban on smoking medical marijuana. The new law provides patients the ability to access medicine in the form their doctor determines best for them, whether it's smoking medical marijuana or utilizing other delivery systems.
TORONTO , March 28, 2019 /CNW/ - Liberty Health Sciences Inc. (LHS.CN) (OTCQX: LHSIF)www.libertyhealthsciences.com ("Liberty" or the "Company"), a provider of high quality cannabis, announced today that it has entered into an in-licensed agreement with The Werc Shop for its patented and patent-pending terpene technology. The Werc Shop is a world-renowned scientific consulting group recognized as the leaders in cannabis terpene analysis and terpene-based formulations, and its cutting-edge technology will enable Liberty to provide superior, standardized, and consistent medical cannabis products to the Florida market. "We are excited to be working with such a powerful technology," said Victor E. Mancebo , interim Chief Executive Officer of Liberty.
TORONTO , March 25, 2019 /CNW/ - Liberty Health Sciences Inc. (LHS.CN) (OTCQX: LHSIF) www.libertyhealthsciences.com ("Liberty" or the "Company"), a provider of high quality cannabis, announced today that it has received Florida Department of Health (DOH) approval to sell whole flower smokable products to patients in Florida , making it one of the first companies in the state to provide smokable medical marijuana in all of its dispensaries. The Company is awaiting DOH approval to provide pre-rolls to patients.
TORONTO , March 15, 2019 /CNW/ - Liberty Health Sciences Inc. (LHS.CN) (OTCQX: LHSIF) www.libertyhealthsciences.com ("Liberty" or the "Company"), a provider of high quality cannabis, announced today that the Company is continuing its expansion in Florida and is on schedule to open its 12th dispensary in Gainesville, FL on March 20, 2019 , subject to the receipt of Florida Department of Health approvals. The Gainesville area is also home to two Liberty facilities that house an aggregate of 228,880 square feet of cultivation space. Located at 12 SW 2nd Street, Gainesville, FL , the new dispensary will be open Monday through Friday, 10 a.m. to 7 p.m. , Saturday, 10 a.m. to 5 p.m. , and Sunday 12 p.m. to 5 p.m. The 1,934 square-foot Gainesville store will provide experienced staff who continue to guide patients through the purchasing process, provide private consultations and host monthly educational events open to the community to discuss the benefits of medicinal cannabis products.
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Liberty Health Sciences Inc. (“Liberty Health” or “the Company”) (OTC: LHSIF) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between June 28, 2018 and December 3, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before March 8, 2019.
NEW YORK, N.Y., March 07, 2019 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Liberty Health Sciences Inc. (OTC: LHSIF) from June.
NEW YORK, NY / ACCESSWIRE / March 5, 2019 / Pomerantz LLP announces that a class action lawsuit has been filed against, Liberty Health Science Inc. (''Liberty'' or the ''Company'') (LHSIF) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and indexed under 19-cv-00161, is on behalf of a class consisting of all persons and entities, other than Defendants and their affiliates, who purchased or otherwise, acquired Liberty common stock between June 28, 2018, and December 3, 2018, both dates inclusive (the ''Class Period''), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the ''Exchange Act'') and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Law Offices of Howard G. Smith reminds investors of the March 8, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Liberty Health Sciences Inc. (“Liberty” or the “Company”) (OTC: LHSIF) securities between June 28, 2018 and December 3, 2018, inclusive (the ''Class Period''). Liberty investors have until March 8, 2019 to file a lead plaintiff motion. Investors suffering losses on their Liberty investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to firstname.lastname@example.org.
Liberty Health Sciences (CSE: LHS) (OTCQX: LHSIF) announced a new dispensary in Florida and provided an update on its construction project at Liberty 360 Innovation Campus in Gainesville. In addition, the company announced resignations of two board members as part of its strategy to increase its directors and senior executives based in the U.S. New […]The post Liberty Opens New Florida Dispensary, Gets More Cultivation Space in Gainesville appeared first on Market Exclusive.
Canadian cannabis products maker Flowr Corp. (TSXV: FLWR) (OTC: FLWPF) said that it hired celebrated Canadian chef Ryan Reed to develop edible cannabis products for the Flowr brand. Chef Reed is a past winner of Iron Chef and Chopped and Victoria's 2011 Chef of the Year. Vancouver, Canada-based SpeakEasy Cannabis Club Ltd. (CSE: EASY), a late-stage […]The post Cannabis Stock News Daily Roundup March 1 appeared first on Market Exclusive.
If you are a shareholder who purchased Liberty Class A common stock between June 28, 2018, and December 3, 2018, you have until March 8, 2019, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at email@example.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980.
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Liberty Health Sciences, Inc. (Other OTC: LHSIF) (“Liberty” or the “Company”) securities during the period between June 28, 2018 through December 03, 2018 inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until March 08, 2019 to seek appointment as lead plaintiff. If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Liberty securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
TORONTO, Feb. 28, 2019 /PRNewswire/ - Liberty Health Sciences Inc. (CSE:LHS) (LHSIF) www.libertyhealthsciences.com ("Liberty" or the "Company"), a provider of high quality cannabis, announced today that it will be opening its latest dispensary in Orange Park, Florida, on March 1, 2019 pending Florida Department of Health (the "DOH") approvals. In supporting the growth of its dispensary openings, the Company also announced that the first phase of its construction at its Liberty 360 Innovation Campus ("Liberty 360") in Gainesville, Florida has been completed, including required inspections by the DOH, which provides the Company with an additional 80,000 square feet of cultivation space.
TORONTO, Feb. 22, 2019 /PRNewswire/ - Liberty Health Sciences Inc. (CSE:LHS) (OTCQX: LHSIF) www.libertyhealthsciences.com ("Liberty" or the "Company"), as mentioned in the Company's Feb 12, 2019 press release, continues to work towards enhancing its directors and senior executives based in the United States, to more closely align with the US geographical focus of the business. In accordance with this strategy, George Scorsis, the Company's Chief Executive Officer, has resigned and will also be stepping down from his Board position. In the interim, Mr. Scorsis will be replaced by Victor E. Mancebo, the Company's current President who is a resident in the State of Florida and has in-depth knowledge of the Company's day to day operations. Victor's appointment ensures that there will be no need for a ramping up period to become familiar with the Company's operations. Victor will serve as the Company's interim Chief Executive Officer and will be appointed to fill the vacancy on the Board until a replacement is sourced for the role.